September 29, 2026 · High impact · Updated Sep 29, 2026
Merck and Daiichi Sankyo voluntarily withdrew their U.S. application for ifinatamab deruxtecan, a small-cell lung cancer drug, after discussions with the FDA indicated that submitted Phase 2 results did not meet accelerated-approval requirements. This withdrawal raises questions about the drug's future promise despite the setback.
AlphaOS aggregates and analyzes market news to extract structured investment intelligence. Content is for research and education only — not investment advice.
This week
2 of 24 shown
See the full board →Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.
